Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PACB 
Pacific Biosciences of California (PACB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: PACB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $2.11
1 Year Target Price $2.11
| 5 | Strong Buy |
| 1 | Buy |
| 8 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.23% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 351.43M USD | Price to earnings Ratio - | 1Y Target Price 2.11 |
Price to earnings Ratio - | 1Y Target Price 2.11 | ||
Volume (30-day avg) 14 | Beta 1.87 | 52 Weeks Range 0.85 - 2.72 | Updated Date 09/14/2025 |
52 Weeks Range 0.85 - 2.72 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.23 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -112.73% |
Management Effectiveness
Return on Assets (TTM) -33.28% | Return on Equity (TTM) -189.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 735919614 | Price to Sales(TTM) 2.25 |
Enterprise Value 735919614 | Price to Sales(TTM) 2.25 | ||
Enterprise Value to Revenue 4.71 | Enterprise Value to EBITDA -4.15 | Shares Outstanding 300371008 | Shares Floating 298123839 |
Shares Outstanding 300371008 | Shares Floating 298123839 | ||
Percent Insiders 9.05 | Percent Institutions 56.36 |
Upturn AI SWOT
Pacific Biosciences of California
Company Overview
History and Background
Pacific Biosciences of California (PacBio) was founded in 2004. The company is known for its Single Molecule, Real-Time (SMRT) sequencing technology. It went public in 2010. Its initial focus was on developing and commercializing its long-read sequencing platform. Over time, PacBio has expanded its applications and customer base.
Core Business Areas
- Sequencing Systems: Development, manufacturing, and commercialization of long-read sequencing platforms, including the Revio and Sequel systems. These are used for a wide variety of applications in genomics, transcriptomics, and epigenetics.
- Consumables: Sales of reagents and other consumables used with PacBio sequencing systems.
- Services: Providing sequencing services, including project design, sample preparation, data analysis, and support.
Leadership and Structure
Christian Henry is the current CEO. The company operates with a functional organizational structure, with departments focused on R&D, commercial operations, manufacturing, and corporate functions.
Top Products and Market Share
Key Offerings
- Revio: A high-throughput long-read sequencing system. Designed for population-scale studies. Market share data is evolving but represents significant growth potential. Competitors include Illumina (ILMN) and Oxford Nanopore Technologies.
- Sequel II/IIe Systems: Previous generation long-read sequencing platform. Used for a wide range of applications. Competitors include Illumina (ILMN) and Oxford Nanopore Technologies. Specific market share data is not readily available, but contributes significantly to PacBio's revenue.
Market Dynamics
Industry Overview
The genomics sequencing market is experiencing substantial growth, driven by increasing applications in research, diagnostics, and drug discovery. Technological advancements and decreasing sequencing costs are fueling market expansion.
Positioning
PacBio is a key player in the long-read sequencing segment, differentiating itself through its SMRT technology. Its competitive advantage lies in its long read lengths and high accuracy for certain applications like structural variant detection and *de novo* genome assembly.
Total Addressable Market (TAM)
The total addressable market for DNA sequencing is estimated to be in the tens of billions of dollars. PacBio is targeting a significant portion of this TAM by focusing on specific applications where long-read sequencing offers unique advantages. PacBio is well-positioned to capitalize on this growing market.
Upturn SWOT Analysis
Strengths
- Long-read sequencing technology (SMRT)
- High accuracy in certain applications
- Established presence in research market
- Technological innovation
Weaknesses
- Higher cost per base compared to short-read sequencing
- Smaller installed base compared to Illumina
- Dependence on capital equipment sales
Opportunities
- Expanding applications in clinical diagnostics
- Partnerships with pharmaceutical companies
- Growth in emerging markets
- Development of new sequencing technologies
Threats
- Competition from Illumina and Oxford Nanopore
- Technological disruption
- Economic downturn
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- ILMN
- ONT.L
Competitive Landscape
PacBio competes with Illumina and Oxford Nanopore Technologies. PacBio holds an advantage in the long read segment of the market, and Illumina dominates overall sequencing throughput with short read technologies. Oxford Nanopore is another long-read competitor with a disruptive technology.
Major Acquisitions
Circulomics
- Year: 2021
- Acquisition Price (USD millions): 80
- Strategic Rationale: Acquisition of Circulomics enhanced PacBiou2019s sample preparation workflow, improving the quality and yield of DNA for long-read sequencing.
Growth Trajectory and Initiatives
Historical Growth: PacBio has experienced fluctuating growth in revenue, driven by product cycles and market adoption of long-read sequencing. The company has invested heavily in R&D to improve its technology and expand its applications.
Future Projections: Analysts project continued revenue growth for PacBio, driven by increased adoption of Revio and expansion into new markets. Profitability is expected to improve over time. Estimates vary widely among analysts.
Recent Initiatives: PacBio has recently launched the Revio system, expanded its partnerships, and focused on increasing its commercial presence in key markets.
Summary
Pacific Biosciences is a key player in the long-read sequencing market with promising technology. The company needs to improve its profitability, and increase its market presence against Illumina and Oxford Nanopore Technologies to become a dominate force. Revio's sucess in the market will be a key factor in how successful they are against their competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Company press releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pacific Biosciences of California
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 2010-10-27 | President, CEO & Director Mr. Christian O. Henry M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 575 | Website https://www.pacb.com |
Full time employees 575 | Website https://www.pacb.com | ||
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.